New drug duo targets hard-to-treat bile duct cancer
Disease control
Recruiting now
This study tests a combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has not responded to standard first-line therapy. The trial has two phases: first to find the safest dose, then to s…
Phase: PHASE1, PHASE2 • Sponsor: Genfit • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC